Cilastatin is a potent renal dehydropeptidase-I inhibitor used in clinical practice primarily in combination with carbapenem antibiotics, such as imipenem, to prevent their metabolic degradation in the… Read more









































Cilastatin is a potent renal dehydropeptidase-I inhibitor used in clinical practice primarily in combination with carbapenem antibiotics, such as imipenem, to prevent their metabolic degradation in the kidneys and improve their therapeutic efficacy. This category includes high-quality reference standards for cilastatin, alongside a comprehensive range of related compounds including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled variants. Pharmaceutical laboratories rely on these specialized materials for rigorous analytical testing, impurity profiling, and method validation during drug development and quality control processes. By providing accurate benchmarks, these standards ensure the precision of stability-indicating assays and help maintain the integrity of the finished drug substance. These products support the characterization and quantification of potential degradation products or synthesis-related impurities, which are essential for regulatory compliance and safety assessments during the manufacture of this critical therapeutic agent.